APSR2026-379

 
Late-Breaking
Submitted
Poster Presentation
 
AP05-018
P121
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1219290-46904-Poster version 27th Oct 2026_435106.pdf
Format: PDF Only
12. Bronchoscopy and Interventional Techniques
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Avinash Anil Nair * Amala Institute of Medical Sciences Department of Pulmonary Medicine Thrissur India
Thomas Vadakkan - Amala Institute of Medical Sciences Department of Pulmonary Medicine Thrissur India
Lisna K - Amala Institute of Medical Sciences Department of Pulmonary Medicine Thrissur India
Savithri M C - Amala Institute of Medical Sciences Department of Pathology Thrissur India
Paul T Antony - Amala Institute of Medical Sciences Department of Rheumatology Thrissur India
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Avinash
Anil Nair
avinash444@hotmail.com
+919159143854
31-40
India
Case Report
Methotrexate-Induced Eosinophilic Pleural Effusion in Primary Sjögren’s Syndrome: A Rare Cause of Drug-Induced Pleural Effusion
Maximum 25 words
Abstract Content
 
 
 
 
Eosinophilic pleural effusion (EPE), defined by the presence of ≥10% eosinophils in pleural fluid, represents an uncommon subtype of pleural effusion with a broad differential diagnosis including malignancy, infections, pulmonary embolism, autoimmune diseases, trauma, and drug reactions. Although malignancy and infections account for many cases, drug-induced EPE remains an underrecognized entity. Methotrexate is widely used in the management of autoimmune diseases and is known to cause pulmonary toxicity, most commonly hypersensitivity pneumonitis. However, methotrexate-associated eosinophilic pleural effusion is exceedingly rare and may pose a diagnostic challenge.
A female in her 50s with a two-year history of primary Sjögren’s syndrome receiving hydroxychloroquine (200 mg daily) and methotrexate (15 mg weekly for six months) presented with left-sided chest pain and shortness of breath. Physical examination revealed reduced chest expansion and diminished breath sounds over the left lower lung zones and chest xray confirmed left pleural effusion.Laboratory evaluation demonstrated peripheral eosinophilia (16%, absolute eosinophil count 800/µL). Pleural fluid analysis revealed an exudative effusion with marked eosinophilia (78%) and low adenosine deaminase levels. Comprehensive evaluation excluded common etiologies. Microbiological investigations including Ziehl–Neelsen staining, Gram staining, fungal staining, pleural fluid cultures, and CBNAAT for Mycobacterium tuberculosis were negative. Stool examination and interferon-gamma release assay excluded parasitic and latent tuberculosis infection. Autoimmune and malignancy screening, including ANA, ANCA, rheumatoid factor, carcinoembryonic antigen, and CA-125, were unremarkable. Thoracoscopy demonstrated grossly normal pleura except for a small subpleural lipoma, while pleural biopsy revealed dense eosinophilic inflammatory infiltrates consistent with eosinophilic pleuritis. Following exclusion of other causes, methotrexate-induced eosinophilic pleural effusion was suspected, and withdrawal of methotrexate resulted in clinical improvement.
Methotrexate-associated eosinophilic pleural effusion is rare and remains a diagnosis of exclusion. This case highlights the importance of considering drug-induced etiologies in patients presenting with eosinophilic pleural effusion after common causes have been excluded. Early recognition and discontinuation of the offending drug may lead to clinical resolution and prevent unnecessary investigations.
 
 
No
Yes
https://storage.unitedwebnetwork.com/files/1285/1219290-37089-Pleuralbiopsy_379420.jpg
JPG or JPEG or PNG format ONLY
Eosinophilic pleural effusion; Methotrexate; Drug-induced pleural disease
maximum 3 keywords and no abbreviations, separated by commas
The authors thank the Departments of Pulmonary Medicine, Pathology and Rheumatology and the clinical staff involved in the care of this patient for their support in diagnosis and management. The authors declare no conflicts of interest. No external funding was received.
317